insights_auto
Outlook: 40.0% bullish·10.0% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
223,76 $
arrow_downward
-1,44%(-3,26) 1D
13 հոկ, 14:29:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
228,93 $
High
229,52 $
Low
221,56 $
Mkt. cap
29,94 մլրդ
Avg. vol.
1,46 մլն
Volume
472,72 հզր
P/E ratio
38,08
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 մլն
No. of employees
2 հզր
Open
228,93 $
High
229,52 $
Low
221,56 $
Mkt. cap
29,94 մլրդ
Avg. vol.
1,46 մլն
Volume
472,72 հզր
P/E ratio
38,08
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Investing.com Canada
·
10 ժամ առաջ
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
The Globe and Mail
·
19 ժամ առաջ
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Solventum Corporation (SOLV)
Stocks Down Under
·
23 ժամ առաջ
Alnylam Pharmaceuticals (NDQ:ALNY): This RNAi Pioneer Is Becoming A Cardiometabolic Heavyweight Right Before Our Eyes
Investing.com
·
2 օր առաջ
Alnylam EVP Bryan Supran sells $398,855 in shares
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.